Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments.
Pons-Riverola A, Morillas H, Berdejo J, Pernas S, Pomares H, Asiain L, Garay A, Fernandez-Ortega A, Oliveira AC, Martínez E, Jiménez-Marrero S, Pina E, Fort E, Ramos R, Alcoberro L, Hidalgo E, Antonio-Rebollo M, Alcober L, Enjuanes Grau C, Comín-Colet J, Moliner P. Pons-Riverola A, et al. Among authors: fernandez ortega a. Cancers (Basel). 2023 Dec 18;15(24):5885. doi: 10.3390/cancers15245885. Cancers (Basel). 2023. PMID: 38136428 Free PMC article. Review.
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A. Pernas S, et al. Among authors: fernandez ortega a. Front Oncol. 2019 Aug 6;9:707. doi: 10.3389/fonc.2019.00707. eCollection 2019. Front Oncol. 2019. PMID: 31448227 Free PMC article.
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A. Pernas S, et al. Among authors: fernandez ortega a. Front Oncol. 2019 Sep 25;9:967. doi: 10.3389/fonc.2019.00967. eCollection 2019. Front Oncol. 2019. PMID: 31598491 Free PMC article.
Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB, Fernández-Ortega A, Stradella A, Morilla I, Falo C, Vázquez S, Castany R, Villanueva R, Recalde S, Pérez VN, Gil-Gil M, Pernas S. Sirvén MB, et al. Among authors: fernandez ortega a. BMC Pharmacol Toxicol. 2019 Nov 21;20(1):68. doi: 10.1186/s40360-019-0367-x. BMC Pharmacol Toxicol. 2019. PMID: 31753013 Free PMC article.
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Gil-Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, Saura C, Fernández-Ortega A, Garcia-Martinez E, Martinez-Jañez N, Melé M, Villagrasa P, Celiz P, Perez Martin X, Ciruelos E, Pernas S. Gil-Gil MJ, et al. Among authors: fernandez ortega a. Front Oncol. 2021 Jul 9;11:645026. doi: 10.3389/fonc.2021.645026. eCollection 2021. Front Oncol. 2021. PMID: 34307126 Free PMC article.
Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
Stradella A, Gargallo P, Cejuela M, Petit A, Bosch-Schips J, Carbonell P, Recalde S, Vethencourt A, Fernandez-Ortega A, Falo C, Gil-Gil M, Vázquez S, Obadia V, Villanueva-Vázquez R, Soler-Monsó T, Calabria I, Pernas S. Stradella A, et al. Among authors: fernandez ortega a. Mod Pathol. 2022 Aug;35(8):1066-1074. doi: 10.1038/s41379-022-01017-7. Epub 2022 Feb 17. Mod Pathol. 2022. PMID: 35177782 Free article.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.
Llombart-Cussac A, Pérez-Garcia JM, Ruiz Borrego M, Tolosa P, Blanch S, Fernández-Ortega A, Urruticoechea A, Blancas I, Saura C, Rojas B, Bermejo B, Ponce Lorenzo J, Gion M, Cortez-Castedo P, Llabres E, Galve E, Cueva JF, López A, Alonso-Romero JL, González-Santiago S, Martínez de Dueñas E, Ciruelos E, Martrat G, Gener P, Alcalá-López D, Sampayo-Cordero M, Gómez-Peralta F, Cortés J. Llombart-Cussac A, et al. Among authors: fernandez ortega a. EClinicalMedicine. 2024 Apr 11;71:102520. doi: 10.1016/j.eclinm.2024.102520. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38638399 Free PMC article.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
[Therapeutic non-compliance with insulin in the treatment of diabetes mellitus 2].
Márquez Contreras E, Martell Claros N, Gil Guillén V, Casado Martínez JJ, Martín de Pablos JL, Ferraro García J, Chaves González R, Fernández Ortega A; Grupo de Trabajo sobre Cumplimiento de la Asociación de la Sociedad española de Hipertensión Arterial y Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA). Márquez Contreras E, et al. Among authors: fernandez ortega a. Aten Primaria. 2012 Feb;44(2):74-81. doi: 10.1016/j.aprim.2010.11.013. Epub 2011 Oct 22. Aten Primaria. 2012. PMID: 22018796 Free PMC article. Spanish.
17 results